Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance
Clinical Parkinsonism & Related Disorders2024Vol. 10, pp. 100239–100239
Citations Over TimeTop 1% of 2024 papers
Victor S.C. Fung, Jason Aldred, Martha P. Arroyo, Filip Bergquist, Agnita J.W. Boon, Manon Bouchard, Sarah Bray, Sara Dhanani, Maurizio Facheris, Nahome Fisseha, Eric Freire-Álvarez, Robert A. Hauser, Anna Jeong, Jia Jia, Pavnit Kukreja, Michael J. Soileau, Amy M. Spiegel, Saritha Talapala, Arjun Tarakad, Enrique Urrea‐Mendoza, Jorge Zamudio, Rajesh Pahwa
Abstract
Continuous subcutaneous infusion of LDp/CDp represents a promising therapeutic option for individuals with PD. Individualized dose optimization during both daytime and nighttime hours, coupled with patient education, and early recognition of certain adverse events (plus their appropriate management) are required for the success of this minimally invasive and highly efficacious therapy.
Related Papers
- → Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson’s disease(2007)12 cited
- → 20 Things to Know about Deep Brain Stimulation(2014)2 cited
- Deep-brain stimulation extends relief from Parkinson's. Electrodes deep in the brain continue relieving Parkinson's disease symptoms for five years.(2004)
- → The impact of Deep Brain Stimulation on the sexual function of patients with Parkinson’s Disease(2019)
- → Identification of suboptimal response to STN-DBS in Parkinson’s disease(2023)